There were 666 press releases posted in the last 24 hours and 440,917 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Epizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image